nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ALB—atherosclerosis	0.206	1	CbGaD
Vemurafenib—ABCC1—Rosuvastatin—atherosclerosis	0.105	0.201	CbGbCtD
Vemurafenib—ABCG2—Rosuvastatin—atherosclerosis	0.0704	0.134	CbGbCtD
Vemurafenib—ABCG2—Ezetimibe—atherosclerosis	0.0704	0.134	CbGbCtD
Vemurafenib—ABCG2—Pravastatin—atherosclerosis	0.064	0.122	CbGbCtD
Vemurafenib—ALB—Rosuvastatin—atherosclerosis	0.0485	0.0925	CbGbCtD
Vemurafenib—CYP2D6—Niacin—atherosclerosis	0.0281	0.0536	CbGbCtD
Vemurafenib—Keratosis—Niacin—atherosclerosis	0.0232	0.167	CcSEcCtD
Vemurafenib—CYP2D6—Simvastatin—atherosclerosis	0.0222	0.0424	CbGbCtD
Vemurafenib—CYP2D6—Lovastatin—atherosclerosis	0.0218	0.0415	CbGbCtD
Vemurafenib—CYP2D6—Pravastatin—atherosclerosis	0.0218	0.0415	CbGbCtD
Vemurafenib—CYP3A4—Rosuvastatin—atherosclerosis	0.0152	0.029	CbGbCtD
Vemurafenib—CYP3A4—Ezetimibe—atherosclerosis	0.0152	0.029	CbGbCtD
Vemurafenib—CYP3A4—Simvastatin—atherosclerosis	0.0141	0.0269	CbGbCtD
Vemurafenib—CYP3A4—Pravastatin—atherosclerosis	0.0138	0.0264	CbGbCtD
Vemurafenib—CYP3A4—Lovastatin—atherosclerosis	0.0138	0.0264	CbGbCtD
Vemurafenib—Hyperkeratosis—Niacin—atherosclerosis	0.00389	0.028	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Lovastatin—atherosclerosis	0.00316	0.0227	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Simvastatin—atherosclerosis	0.00295	0.0212	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Pravastatin—atherosclerosis	0.00267	0.0192	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00154	0.0111	CcSEcCtD
Vemurafenib—Neoplasm malignant—Ezetimibe—atherosclerosis	0.00149	0.0107	CcSEcCtD
Vemurafenib—Hepatotoxicity—Niacin—atherosclerosis	0.00144	0.0104	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00133	0.00956	CcSEcCtD
Vemurafenib—Vasculitis—Lovastatin—atherosclerosis	0.00133	0.00953	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Lovastatin—atherosclerosis	0.00131	0.00942	CcSEcCtD
Vemurafenib—Vasculitis—Ezetimibe—atherosclerosis	0.0013	0.00935	CcSEcCtD
Vemurafenib—Vasculitis—Simvastatin—atherosclerosis	0.00124	0.00892	CcSEcCtD
Vemurafenib—Vasculitis—Pravastatin—atherosclerosis	0.00112	0.00806	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Pravastatin—atherosclerosis	0.00111	0.00796	CcSEcCtD
Vemurafenib—Photosensitivity—Lovastatin—atherosclerosis	0.00107	0.00769	CcSEcCtD
Vemurafenib—Photosensitivity—Ezetimibe—atherosclerosis	0.00105	0.00755	CcSEcCtD
Vemurafenib—Rash maculo-papular—Niacin—atherosclerosis	0.00101	0.00726	CcSEcCtD
Vemurafenib—Photosensitivity—Simvastatin—atherosclerosis	0.001	0.0072	CcSEcCtD
Vemurafenib—Arthritis—Lovastatin—atherosclerosis	0.000967	0.00695	CcSEcCtD
Vemurafenib—Arthritis—Ezetimibe—atherosclerosis	0.000948	0.00682	CcSEcCtD
Vemurafenib—Pain in extremity—Lovastatin—atherosclerosis	0.00094	0.00675	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—atherosclerosis	0.000928	1	CrCbGaD
Vemurafenib—Atrial fibrillation—Simvastatin—atherosclerosis	0.000928	0.00667	CcSEcCtD
Vemurafenib—Pain in extremity—Ezetimibe—atherosclerosis	0.000922	0.00663	CcSEcCtD
Vemurafenib—Photosensitivity—Pravastatin—atherosclerosis	0.000905	0.00651	CcSEcCtD
Vemurafenib—Arthritis—Simvastatin—atherosclerosis	0.000904	0.0065	CcSEcCtD
Vemurafenib—Atrial fibrillation—Niacin—atherosclerosis	0.000852	0.00612	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.000846	0.00608	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.000838	0.00602	CcSEcCtD
Vemurafenib—Arthritis—Niacin—atherosclerosis	0.00083	0.00597	CcSEcCtD
Vemurafenib—Arthritis—Pravastatin—atherosclerosis	0.000818	0.00588	CcSEcCtD
Vemurafenib—Eosinophilia—Lovastatin—atherosclerosis	0.000804	0.00578	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.000792	0.00569	CcSEcCtD
Vemurafenib—Eosinophilia—Ezetimibe—atherosclerosis	0.000789	0.00567	CcSEcCtD
Vemurafenib—Eosinophilia—Simvastatin—atherosclerosis	0.000752	0.00541	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Lovastatin—atherosclerosis	0.000741	0.00533	CcSEcCtD
Vemurafenib—Dry skin—Niacin—atherosclerosis	0.00074	0.00532	CcSEcCtD
Vemurafenib—Dry skin—Pravastatin—atherosclerosis	0.000728	0.00524	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.000727	0.00523	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000718	0.00516	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000716	0.00514	CcSEcCtD
Vemurafenib—Infestation—Ezetimibe—atherosclerosis	0.00071	0.00511	CcSEcCtD
Vemurafenib—Infestation NOS—Ezetimibe—atherosclerosis	0.00071	0.00511	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00071	0.0051	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.000696	0.005	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000693	0.00498	CcSEcCtD
Vemurafenib—Eosinophilia—Pravastatin—atherosclerosis	0.00068	0.00489	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000672	0.00483	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000664	0.00477	CcSEcCtD
Vemurafenib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000628	0.00452	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000627	0.00451	CcSEcCtD
Vemurafenib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000627	0.0045	CcSEcCtD
Vemurafenib—Weight decreased—Pravastatin—atherosclerosis	0.000621	0.00447	CcSEcCtD
Vemurafenib—Erythema multiforme—Lovastatin—atherosclerosis	0.000615	0.00442	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000607	0.00436	CcSEcCtD
Vemurafenib—Erythema multiforme—Ezetimibe—atherosclerosis	0.000603	0.00433	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Pravastatin—atherosclerosis	0.0006	0.00431	CcSEcCtD
Vemurafenib—Chills—Lovastatin—atherosclerosis	0.000583	0.00419	CcSEcCtD
Vemurafenib—Cough—Rosuvastatin—atherosclerosis	0.000583	0.00419	CcSEcCtD
Vemurafenib—Angiopathy—Ezetimibe—atherosclerosis	0.000579	0.00416	CcSEcCtD
Vemurafenib—Erythema multiforme—Simvastatin—atherosclerosis	0.000575	0.00413	CcSEcCtD
Vemurafenib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000575	0.00413	CcSEcCtD
Vemurafenib—Alopecia—Lovastatin—atherosclerosis	0.000575	0.00413	CcSEcCtD
Vemurafenib—Myalgia—Rosuvastatin—atherosclerosis	0.000569	0.00409	CcSEcCtD
Vemurafenib—Arthralgia—Rosuvastatin—atherosclerosis	0.000569	0.00409	CcSEcCtD
Vemurafenib—Alopecia—Ezetimibe—atherosclerosis	0.000563	0.00405	CcSEcCtD
Vemurafenib—Erythema—Ezetimibe—atherosclerosis	0.000555	0.00399	CcSEcCtD
Vemurafenib—Malnutrition—Ezetimibe—atherosclerosis	0.000555	0.00399	CcSEcCtD
Vemurafenib—Dysgeusia—Lovastatin—atherosclerosis	0.000554	0.00398	CcSEcCtD
Vemurafenib—Oedema peripheral—Niacin—atherosclerosis	0.00055	0.00395	CcSEcCtD
Vemurafenib—Back pain—Lovastatin—atherosclerosis	0.000547	0.00393	CcSEcCtD
Vemurafenib—Chills—Simvastatin—atherosclerosis	0.000546	0.00392	CcSEcCtD
Vemurafenib—Infection—Rosuvastatin—atherosclerosis	0.000541	0.00389	CcSEcCtD
Vemurafenib—Alopecia—Simvastatin—atherosclerosis	0.000537	0.00386	CcSEcCtD
Vemurafenib—Back pain—Ezetimibe—atherosclerosis	0.000537	0.00386	CcSEcCtD
Vemurafenib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000535	0.00384	CcSEcCtD
Vemurafenib—Erythema—Simvastatin—atherosclerosis	0.000529	0.0038	CcSEcCtD
Vemurafenib—Eye disorder—Niacin—atherosclerosis	0.000522	0.00375	CcSEcCtD
Vemurafenib—Erythema multiforme—Pravastatin—atherosclerosis	0.00052	0.00374	CcSEcCtD
Vemurafenib—Dysgeusia—Simvastatin—atherosclerosis	0.000518	0.00373	CcSEcCtD
Vemurafenib—Cardiac disorder—Pravastatin—atherosclerosis	0.00051	0.00367	CcSEcCtD
Vemurafenib—Angiopathy—Niacin—atherosclerosis	0.000507	0.00364	CcSEcCtD
Vemurafenib—Chills—Niacin—atherosclerosis	0.000501	0.0036	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000497	0.00357	CcSEcCtD
Vemurafenib—Alopecia—Niacin—atherosclerosis	0.000493	0.00355	CcSEcCtD
Vemurafenib—Chills—Pravastatin—atherosclerosis	0.000493	0.00355	CcSEcCtD
Vemurafenib—Malnutrition—Niacin—atherosclerosis	0.000486	0.00349	CcSEcCtD
Vemurafenib—Erythema—Niacin—atherosclerosis	0.000486	0.00349	CcSEcCtD
Vemurafenib—Alopecia—Pravastatin—atherosclerosis	0.000486	0.00349	CcSEcCtD
Vemurafenib—Cough—Ezetimibe—atherosclerosis	0.000484	0.00348	CcSEcCtD
Vemurafenib—Myalgia—Lovastatin—atherosclerosis	0.000482	0.00346	CcSEcCtD
Vemurafenib—Arthralgia—Lovastatin—atherosclerosis	0.000482	0.00346	CcSEcCtD
Vemurafenib—Arthralgia—Ezetimibe—atherosclerosis	0.000473	0.0034	CcSEcCtD
Vemurafenib—Myalgia—Ezetimibe—atherosclerosis	0.000473	0.0034	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000469	0.00337	CcSEcCtD
Vemurafenib—Dysgeusia—Pravastatin—atherosclerosis	0.000469	0.00337	CcSEcCtD
Vemurafenib—Constipation—Rosuvastatin—atherosclerosis	0.000466	0.00335	CcSEcCtD
Vemurafenib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000462	0.00332	CcSEcCtD
Vemurafenib—Infection—Lovastatin—atherosclerosis	0.000459	0.0033	CcSEcCtD
Vemurafenib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000453	0.00326	CcSEcCtD
Vemurafenib—Myalgia—Simvastatin—atherosclerosis	0.000451	0.00324	CcSEcCtD
Vemurafenib—Arthralgia—Simvastatin—atherosclerosis	0.000451	0.00324	CcSEcCtD
Vemurafenib—Infection—Ezetimibe—atherosclerosis	0.00045	0.00324	CcSEcCtD
Vemurafenib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000444	0.00319	CcSEcCtD
Vemurafenib—Skin disorder—Ezetimibe—atherosclerosis	0.00044	0.00316	CcSEcCtD
Vemurafenib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000432	0.00311	CcSEcCtD
Vemurafenib—Infection—Simvastatin—atherosclerosis	0.000429	0.00309	CcSEcCtD
Vemurafenib—Cough—Niacin—atherosclerosis	0.000424	0.00305	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000421	0.00302	CcSEcCtD
Vemurafenib—Cough—Pravastatin—atherosclerosis	0.000418	0.003	CcSEcCtD
Vemurafenib—Arthralgia—Niacin—atherosclerosis	0.000414	0.00297	CcSEcCtD
Vemurafenib—Myalgia—Niacin—atherosclerosis	0.000414	0.00297	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000413	0.00297	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000411	0.00295	CcSEcCtD
Vemurafenib—Arthralgia—Pravastatin—atherosclerosis	0.000407	0.00293	CcSEcCtD
Vemurafenib—Myalgia—Pravastatin—atherosclerosis	0.000407	0.00293	CcSEcCtD
Vemurafenib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000402	0.00289	CcSEcCtD
Vemurafenib—Decreased appetite—Lovastatin—atherosclerosis	0.000402	0.00289	CcSEcCtD
Vemurafenib—Fatigue—Lovastatin—atherosclerosis	0.000398	0.00286	CcSEcCtD
Vemurafenib—Anaphylactic shock—Niacin—atherosclerosis	0.000397	0.00285	CcSEcCtD
Vemurafenib—Constipation—Lovastatin—atherosclerosis	0.000395	0.00284	CcSEcCtD
Vemurafenib—Decreased appetite—Ezetimibe—atherosclerosis	0.000394	0.00283	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000394	0.00283	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000391	0.00281	CcSEcCtD
Vemurafenib—Asthenia—Rosuvastatin—atherosclerosis	0.000391	0.00281	CcSEcCtD
Vemurafenib—Anaphylactic shock—Pravastatin—atherosclerosis	0.000391	0.00281	CcSEcCtD
Vemurafenib—Fatigue—Ezetimibe—atherosclerosis	0.000391	0.00281	CcSEcCtD
Vemurafenib—Infection—Pravastatin—atherosclerosis	0.000388	0.00279	CcSEcCtD
Vemurafenib—Constipation—Ezetimibe—atherosclerosis	0.000387	0.00278	CcSEcCtD
Vemurafenib—Pruritus—Rosuvastatin—atherosclerosis	0.000386	0.00277	CcSEcCtD
Vemurafenib—Skin disorder—Niacin—atherosclerosis	0.000385	0.00277	CcSEcCtD
Vemurafenib—Decreased appetite—Simvastatin—atherosclerosis	0.000376	0.0027	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000373	0.00268	CcSEcCtD
Vemurafenib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000373	0.00268	CcSEcCtD
Vemurafenib—Fatigue—Simvastatin—atherosclerosis	0.000372	0.00268	CcSEcCtD
Vemurafenib—Hypotension—Niacin—atherosclerosis	0.000371	0.00266	CcSEcCtD
Vemurafenib—Constipation—Simvastatin—atherosclerosis	0.000369	0.00266	CcSEcCtD
Vemurafenib—Body temperature increased—Lovastatin—atherosclerosis	0.000365	0.00262	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000361	0.0026	CcSEcCtD
Vemurafenib—Dizziness—Rosuvastatin—atherosclerosis	0.00036	0.00259	CcSEcCtD
Vemurafenib—Body temperature increased—Ezetimibe—atherosclerosis	0.000358	0.00257	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000356	0.00256	CcSEcCtD
Vemurafenib—Decreased appetite—Niacin—atherosclerosis	0.000345	0.00248	CcSEcCtD
Vemurafenib—Rash—Rosuvastatin—atherosclerosis	0.000344	0.00247	CcSEcCtD
Vemurafenib—Dermatitis—Rosuvastatin—atherosclerosis	0.000343	0.00247	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000342	0.00246	CcSEcCtD
Vemurafenib—Body temperature increased—Simvastatin—atherosclerosis	0.000342	0.00245	CcSEcCtD
Vemurafenib—Headache—Rosuvastatin—atherosclerosis	0.000341	0.00245	CcSEcCtD
Vemurafenib—Hypersensitivity—Lovastatin—atherosclerosis	0.00034	0.00245	CcSEcCtD
Vemurafenib—Decreased appetite—Pravastatin—atherosclerosis	0.00034	0.00244	CcSEcCtD
Vemurafenib—Fatigue—Pravastatin—atherosclerosis	0.000337	0.00242	CcSEcCtD
Vemurafenib—Constipation—Pravastatin—atherosclerosis	0.000334	0.0024	CcSEcCtD
Vemurafenib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000334	0.0024	CcSEcCtD
Vemurafenib—Asthenia—Lovastatin—atherosclerosis	0.000331	0.00238	CcSEcCtD
Vemurafenib—Pruritus—Lovastatin—atherosclerosis	0.000327	0.00235	CcSEcCtD
Vemurafenib—Asthenia—Ezetimibe—atherosclerosis	0.000325	0.00234	CcSEcCtD
Vemurafenib—Nausea—Rosuvastatin—atherosclerosis	0.000324	0.00233	CcSEcCtD
Vemurafenib—Pruritus—Ezetimibe—atherosclerosis	0.000321	0.0023	CcSEcCtD
Vemurafenib—Hypersensitivity—Simvastatin—atherosclerosis	0.000318	0.00229	CcSEcCtD
Vemurafenib—Diarrhoea—Lovastatin—atherosclerosis	0.000316	0.00227	CcSEcCtD
Vemurafenib—Body temperature increased—Niacin—atherosclerosis	0.000314	0.00225	CcSEcCtD
Vemurafenib—Asthenia—Simvastatin—atherosclerosis	0.00031	0.00223	CcSEcCtD
Vemurafenib—Diarrhoea—Ezetimibe—atherosclerosis	0.00031	0.00223	CcSEcCtD
Vemurafenib—Body temperature increased—Pravastatin—atherosclerosis	0.000309	0.00222	CcSEcCtD
Vemurafenib—Pruritus—Simvastatin—atherosclerosis	0.000306	0.0022	CcSEcCtD
Vemurafenib—Dizziness—Lovastatin—atherosclerosis	0.000305	0.0022	CcSEcCtD
Vemurafenib—Dizziness—Ezetimibe—atherosclerosis	0.0003	0.00215	CcSEcCtD
Vemurafenib—Diarrhoea—Simvastatin—atherosclerosis	0.000296	0.00212	CcSEcCtD
Vemurafenib—Vomiting—Lovastatin—atherosclerosis	0.000294	0.00211	CcSEcCtD
Vemurafenib—Hypersensitivity—Niacin—atherosclerosis	0.000292	0.0021	CcSEcCtD
Vemurafenib—Rash—Lovastatin—atherosclerosis	0.000291	0.00209	CcSEcCtD
Vemurafenib—Dermatitis—Lovastatin—atherosclerosis	0.000291	0.00209	CcSEcCtD
Vemurafenib—Headache—Lovastatin—atherosclerosis	0.000289	0.00208	CcSEcCtD
Vemurafenib—Vomiting—Ezetimibe—atherosclerosis	0.000288	0.00207	CcSEcCtD
Vemurafenib—Hypersensitivity—Pravastatin—atherosclerosis	0.000288	0.00207	CcSEcCtD
Vemurafenib—Dizziness—Simvastatin—atherosclerosis	0.000286	0.00205	CcSEcCtD
Vemurafenib—Rash—Ezetimibe—atherosclerosis	0.000286	0.00205	CcSEcCtD
Vemurafenib—Dermatitis—Ezetimibe—atherosclerosis	0.000285	0.00205	CcSEcCtD
Vemurafenib—Asthenia—Niacin—atherosclerosis	0.000285	0.00205	CcSEcCtD
Vemurafenib—Headache—Ezetimibe—atherosclerosis	0.000284	0.00204	CcSEcCtD
Vemurafenib—Pruritus—Niacin—atherosclerosis	0.000281	0.00202	CcSEcCtD
Vemurafenib—Asthenia—Pravastatin—atherosclerosis	0.00028	0.00201	CcSEcCtD
Vemurafenib—Pruritus—Pravastatin—atherosclerosis	0.000276	0.00199	CcSEcCtD
Vemurafenib—Vomiting—Simvastatin—atherosclerosis	0.000275	0.00197	CcSEcCtD
Vemurafenib—Nausea—Lovastatin—atherosclerosis	0.000274	0.00197	CcSEcCtD
Vemurafenib—Rash—Simvastatin—atherosclerosis	0.000272	0.00196	CcSEcCtD
Vemurafenib—Dermatitis—Simvastatin—atherosclerosis	0.000272	0.00196	CcSEcCtD
Vemurafenib—Diarrhoea—Niacin—atherosclerosis	0.000271	0.00195	CcSEcCtD
Vemurafenib—Headache—Simvastatin—atherosclerosis	0.000271	0.00195	CcSEcCtD
Vemurafenib—Nausea—Ezetimibe—atherosclerosis	0.000269	0.00193	CcSEcCtD
Vemurafenib—Diarrhoea—Pravastatin—atherosclerosis	0.000267	0.00192	CcSEcCtD
Vemurafenib—Dizziness—Niacin—atherosclerosis	0.000262	0.00189	CcSEcCtD
Vemurafenib—Dizziness—Pravastatin—atherosclerosis	0.000258	0.00186	CcSEcCtD
Vemurafenib—Nausea—Simvastatin—atherosclerosis	0.000257	0.00184	CcSEcCtD
Vemurafenib—Vomiting—Niacin—atherosclerosis	0.000252	0.00181	CcSEcCtD
Vemurafenib—Rash—Niacin—atherosclerosis	0.00025	0.0018	CcSEcCtD
Vemurafenib—Dermatitis—Niacin—atherosclerosis	0.00025	0.0018	CcSEcCtD
Vemurafenib—Headache—Niacin—atherosclerosis	0.000249	0.00179	CcSEcCtD
Vemurafenib—Vomiting—Pravastatin—atherosclerosis	0.000248	0.00179	CcSEcCtD
Vemurafenib—Rash—Pravastatin—atherosclerosis	0.000246	0.00177	CcSEcCtD
Vemurafenib—Dermatitis—Pravastatin—atherosclerosis	0.000246	0.00177	CcSEcCtD
Vemurafenib—Headache—Pravastatin—atherosclerosis	0.000245	0.00176	CcSEcCtD
Vemurafenib—Nausea—Niacin—atherosclerosis	0.000236	0.00169	CcSEcCtD
Vemurafenib—Nausea—Pravastatin—atherosclerosis	0.000232	0.00167	CcSEcCtD
Vemurafenib—BRAF—Signaling Pathways—IGF1—atherosclerosis	9.69e-06	7.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LPL—atherosclerosis	9.68e-06	7.46e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—atherosclerosis	9.65e-06	7.44e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—atherosclerosis	9.62e-06	7.41e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CD36—atherosclerosis	9.59e-06	7.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	9.55e-06	7.36e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAV1—atherosclerosis	9.53e-06	7.34e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOA1—atherosclerosis	9.51e-06	7.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALOX5—atherosclerosis	9.46e-06	7.29e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SCARB1—atherosclerosis	9.43e-06	7.27e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOA2—atherosclerosis	9.42e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	9.42e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALOX15—atherosclerosis	9.42e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	9.42e-06	7.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PRKCG—atherosclerosis	9.41e-06	7.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCG5—atherosclerosis	9.31e-06	7.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	9.3e-06	7.16e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SERPINE1—atherosclerosis	9.2e-06	7.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—atherosclerosis	9.17e-06	7.06e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG1—atherosclerosis	9.15e-06	7.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—atherosclerosis	9.13e-06	7.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—atherosclerosis	9.11e-06	7.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SERPINE1—atherosclerosis	9.09e-06	7.01e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—atherosclerosis	9.09e-06	7.01e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SERPINE1—atherosclerosis	9.01e-06	6.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPA—atherosclerosis	8.99e-06	6.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—atherosclerosis	8.97e-06	6.91e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—atherosclerosis	8.95e-06	6.9e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARA—atherosclerosis	8.92e-06	6.87e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMGCR—atherosclerosis	8.91e-06	6.86e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—atherosclerosis	8.79e-06	6.77e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BGN—atherosclerosis	8.71e-06	6.71e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CG—atherosclerosis	8.68e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—atherosclerosis	8.68e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	8.64e-06	6.66e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AGT—atherosclerosis	8.64e-06	6.66e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOA5—atherosclerosis	8.62e-06	6.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FABP4—atherosclerosis	8.61e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LCAT—atherosclerosis	8.61e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	8.61e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—atherosclerosis	8.6e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MAPK3—atherosclerosis	8.55e-06	6.59e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NAMPT—atherosclerosis	8.48e-06	6.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDGFB—atherosclerosis	8.48e-06	6.54e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—atherosclerosis	8.46e-06	6.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA4—atherosclerosis	8.45e-06	6.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LIPC—atherosclerosis	8.43e-06	6.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—atherosclerosis	8.4e-06	6.47e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAV1—atherosclerosis	8.39e-06	6.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—atherosclerosis	8.38e-06	6.46e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOC3—atherosclerosis	8.38e-06	6.46e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	8.37e-06	6.45e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOA1—atherosclerosis	8.37e-06	6.45e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LDLR—atherosclerosis	8.33e-06	6.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP7A1—atherosclerosis	8.3e-06	6.4e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—atherosclerosis	8.3e-06	6.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	8.3e-06	6.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGT—atherosclerosis	8.28e-06	6.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—atherosclerosis	8.24e-06	6.35e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—INS—atherosclerosis	8.22e-06	6.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	8.2e-06	6.32e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CETP—atherosclerosis	8.13e-06	6.27e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	8.13e-06	6.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—atherosclerosis	8.11e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—atherosclerosis	8.11e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	8.11e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—atherosclerosis	8.04e-06	6.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CAV1—atherosclerosis	8.04e-06	6.19e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.04e-06	6.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOA1—atherosclerosis	8.02e-06	6.18e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALOX5—atherosclerosis	8.01e-06	6.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—atherosclerosis	8e-06	6.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCA1—atherosclerosis	7.94e-06	6.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—atherosclerosis	7.94e-06	6.12e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—atherosclerosis	7.87e-06	6.06e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—atherosclerosis	7.79e-06	6.01e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SCARB1—atherosclerosis	7.79e-06	6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ESR1—atherosclerosis	7.75e-06	5.97e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP27A1—atherosclerosis	7.67e-06	5.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—F2—atherosclerosis	7.65e-06	5.9e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CG—atherosclerosis	7.64e-06	5.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—atherosclerosis	7.53e-06	5.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NFKB1—atherosclerosis	7.46e-06	5.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—atherosclerosis	7.42e-06	5.72e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	7.4e-06	5.7e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—atherosclerosis	7.37e-06	5.68e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMGCR—atherosclerosis	7.36e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK8—atherosclerosis	7.34e-06	5.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CG—atherosclerosis	7.32e-06	5.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	7.27e-06	5.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA2—atherosclerosis	7.27e-06	5.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALOX15—atherosclerosis	7.27e-06	5.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	7.27e-06	5.6e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—INS—atherosclerosis	7.23e-06	5.57e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—atherosclerosis	7.21e-06	5.55e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NAMPT—atherosclerosis	7.19e-06	5.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG5—atherosclerosis	7.18e-06	5.54e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	7.14e-06	5.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LIPC—atherosclerosis	7.14e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—atherosclerosis	7.13e-06	5.49e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOC3—atherosclerosis	7.1e-06	5.47e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LDLR—atherosclerosis	7.05e-06	5.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—atherosclerosis	7.05e-06	5.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK3—atherosclerosis	7.01e-06	5.4e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NFKB1—atherosclerosis	6.97e-06	5.37e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—atherosclerosis	6.95e-06	5.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPA—atherosclerosis	6.94e-06	5.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INS—atherosclerosis	6.93e-06	5.34e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CETP—atherosclerosis	6.89e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK8—atherosclerosis	6.86e-06	5.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—atherosclerosis	6.82e-06	5.26e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—atherosclerosis	6.81e-06	5.25e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BGN—atherosclerosis	6.72e-06	5.18e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—atherosclerosis	6.71e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—atherosclerosis	6.7e-06	5.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA5—atherosclerosis	6.65e-06	5.13e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—atherosclerosis	6.63e-06	5.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SCARB1—atherosclerosis	6.6e-06	5.08e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—atherosclerosis	6.59e-06	5.08e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK3—atherosclerosis	6.58e-06	5.07e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCA1—atherosclerosis	6.56e-06	5.05e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOB—atherosclerosis	6.53e-06	5.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.42e-06	4.95e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK3—atherosclerosis	6.41e-06	4.94e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.4e-06	4.93e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—atherosclerosis	6.38e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—atherosclerosis	6.37e-06	4.91e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—atherosclerosis	6.35e-06	4.89e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—atherosclerosis	6.34e-06	4.89e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—atherosclerosis	6.33e-06	4.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—atherosclerosis	6.27e-06	4.83e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—atherosclerosis	6.25e-06	4.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.23e-06	4.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LPL—atherosclerosis	6.23e-06	4.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—atherosclerosis	6.19e-06	4.77e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.18e-06	4.76e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—atherosclerosis	6.14e-06	4.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—atherosclerosis	6.08e-06	4.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—atherosclerosis	6.08e-06	4.68e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK3—atherosclerosis	5.99e-06	4.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CD36—atherosclerosis	5.92e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK3—atherosclerosis	5.92e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK3—atherosclerosis	5.86e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—atherosclerosis	5.81e-06	4.48e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—atherosclerosis	5.8e-06	4.47e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—atherosclerosis	5.77e-06	4.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—atherosclerosis	5.74e-06	4.42e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—atherosclerosis	5.69e-06	4.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.62e-06	4.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.62e-06	4.33e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—atherosclerosis	5.61e-06	4.32e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.55e-06	4.28e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.55e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LIPC—atherosclerosis	5.51e-06	4.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARA—atherosclerosis	5.5e-06	4.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOC3—atherosclerosis	5.48e-06	4.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LDLR—atherosclerosis	5.44e-06	4.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—atherosclerosis	5.39e-06	4.15e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOB—atherosclerosis	5.39e-06	4.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGT—atherosclerosis	5.33e-06	4.11e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CETP—atherosclerosis	5.32e-06	4.1e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.24e-06	4.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—atherosclerosis	5.22e-06	4.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAV1—atherosclerosis	5.17e-06	3.99e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOA1—atherosclerosis	5.16e-06	3.98e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LPL—atherosclerosis	5.14e-06	3.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—atherosclerosis	5.13e-06	3.95e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.09e-06	3.92e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—atherosclerosis	5.02e-06	3.87e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD36—atherosclerosis	4.89e-06	3.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—atherosclerosis	4.88e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKB1—atherosclerosis	4.83e-06	3.72e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.81e-06	3.71e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—atherosclerosis	4.77e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK8—atherosclerosis	4.74e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—atherosclerosis	4.73e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—atherosclerosis	4.71e-06	3.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—atherosclerosis	4.68e-06	3.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.63e-06	3.57e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOB—atherosclerosis	4.56e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—atherosclerosis	4.55e-06	3.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARA—atherosclerosis	4.54e-06	3.5e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—INS—atherosclerosis	4.46e-06	3.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.44e-06	3.42e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—atherosclerosis	4.44e-06	3.42e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGT—atherosclerosis	4.4e-06	3.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—atherosclerosis	4.38e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—atherosclerosis	4.38e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPL—atherosclerosis	4.36e-06	3.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—atherosclerosis	4.34e-06	3.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—atherosclerosis	4.33e-06	3.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—atherosclerosis	4.32e-06	3.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—atherosclerosis	4.31e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—atherosclerosis	4.29e-06	3.3e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.29e-06	3.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAV1—atherosclerosis	4.27e-06	3.29e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOA1—atherosclerosis	4.26e-06	3.28e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—atherosclerosis	4.25e-06	3.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK3—atherosclerosis	4.14e-06	3.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD36—atherosclerosis	4.14e-06	3.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—atherosclerosis	4.04e-06	3.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—atherosclerosis	4.02e-06	3.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—atherosclerosis	3.99e-06	3.07e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—atherosclerosis	3.96e-06	3.05e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.92e-06	3.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—atherosclerosis	3.91e-06	3.01e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.89e-06	3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARA—atherosclerosis	3.85e-06	2.97e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—atherosclerosis	3.76e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGT—atherosclerosis	3.73e-06	2.87e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—INS—atherosclerosis	3.68e-06	2.84e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.68e-06	2.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—atherosclerosis	3.65e-06	2.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAV1—atherosclerosis	3.62e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOA1—atherosclerosis	3.61e-06	2.78e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—atherosclerosis	3.58e-06	2.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOB—atherosclerosis	3.52e-06	2.71e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.43e-06	2.64e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—atherosclerosis	3.38e-06	2.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPL—atherosclerosis	3.36e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—atherosclerosis	3.31e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.3e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.28e-06	2.53e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—atherosclerosis	3.23e-06	2.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD36—atherosclerosis	3.2e-06	2.46e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—atherosclerosis	3.18e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—INS—atherosclerosis	3.12e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—atherosclerosis	3.03e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.03e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARA—atherosclerosis	2.97e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.95e-06	2.28e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—atherosclerosis	2.91e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGT—atherosclerosis	2.88e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—atherosclerosis	2.86e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—atherosclerosis	2.82e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—atherosclerosis	2.79e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAV1—atherosclerosis	2.79e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA1—atherosclerosis	2.79e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—atherosclerosis	2.74e-06	2.11e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.54e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.5e-06	1.93e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.46e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—INS—atherosclerosis	2.41e-06	1.86e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—atherosclerosis	2.21e-06	1.7e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—atherosclerosis	2.11e-06	1.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.93e-06	1.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—atherosclerosis	1.8e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—atherosclerosis	1.49e-06	1.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—atherosclerosis	1.26e-06	9.69e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—atherosclerosis	9.71e-07	7.48e-06	CbGpPWpGaD
